GlassScriptPhysician profile
Amber M Abrams
NPI 1487036950
$2,813.60
in general payments reported to CMS, 2019-2025
22 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $509 · 2022: $483 · 2023: $569 · 2024: $731 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $545.00 | 2023-2024 | Barostim Neo System |
| Amgen INC. | $359.75 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $248.32 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $242.88 | 2023-2025 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $204.07 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.49 | 2021-2025 | Jardiance |
| Heartflow, INC. | $149.31 | 2025 | |
| Boston Scientific Corporation | $148.25 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $105.97 | 2021-2025 | Camzyos |
| Esperion Therapeutics, INC. | $104.89 | 2021-2023 | Nexletol |
| Pfizer INC. | $101.31 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.63 | 2021-2025 | |
| Abbott Laboratories | $58.30 | 2021-2024 | Ensite Precision, 2nd Gen Centrimag Primary Console |
| Kiniksa Pharmaceuticals International, Plc | $51.30 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $41.18 | 2023-2024 | Inpefa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $39.27 | 2022 | |
| Merck Sharp & Dohme LLC | $34.25 | 2023 | Verquvo |
| Novo Nordisk INC | $30.82 | 2025 | Wegovy |
| Astellas Pharma US INC | $20.16 | 2021 | |
| Scpharmaceuticals INC. | $14.91 | 2025 | |
| Atricure, INC. | $14.83 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.